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Abstract
Summary In a phase 2 study, continued denosumab treat-
ment for up to 8 years was associated with continued gains
in bone mineral density and persistent reductions in bone
turnover markers. Denosumab treatment was well tolerated
throughout the 8-year study.
Introduction The purpose of this study is to present the
effects of 8 years of continued denosumab treatment on
bone mineral density (BMD) and bone turnover markers
(BTM) from a phase 2 study.
Methods In the 4-year parent study, postmenopausal women
with low BMD were randomized to receive placebo, alendr-
onate, or denosumab. After 2 years, subjects were reallo-
cated to continue, discontinue, or discontinue and reinitiate
denosumab; discontinue alendronate; or maintain placebo
for two more years. The parent study was then extended for
4 years where all subjects received denosumab.
Results Of the 262 subjects who completed the parent
study, 200 enrolled in the extension, and of these, 138
completed the extension. For the subjects who received
8 years of continued denosumab treatment, BMD at the
lumbar spine (N088) and total hip (N087) increased by
16.5 and 6.8 %, respectively, compared with their parent
study baseline, and by 5.7 and 1.8 %, respectively,
compared with their extension study baseline. For the
12 subjects in the original placebo group, 4 years of
denosumab resulted in BMD gains comparable with
those observed during the 4 years of denosumab in
the parent study. Reductions in BTM were sustained
over the course of continued denosumab treatment.
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Reductions also were observed when the placebo group
transitioned to denosumab. Adverse event profile was
consistent with previous reports and an aging cohort.
Conclusion Continued denosumab treatment for 8 years
was associated with progressive gains in BMD, persistent
reductions in BTM, and was well tolerated.
Keywords Bone mineral density . Bone turnover markers .
Denosumab . Osteoporosis . RANK ligand
Introduction
Osteoporosis is a chronic disorder of skeletal fragility and
impaired bone strength due to progressive loss of bone
mass, resulting in thinning and increased porosity of cortical
bone and disruption of trabecular architecture. These
changes are the result of an imbalance in bone remodeling
where bone resorption exceeds bone formation. The RANK/
RANK ligand pathway is an important modulator of osteo-
clast activity [1–6]. Increased production of RANK ligand is
implicated as a cause of increased bone remodeling in
postmenopausal women [7, 8].
Denosumab (Prolia®, Amgen Inc., Thousand Oaks, CA)
is a fully human IgG2 antibody that binds to RANK ligand
with very high specificity [9]. By preventing the interaction
of RANK ligand to its receptor RANK, denosumab is a
potent anti-resorptive agent, decreasing the formation, func-
tion, and survival of osteoclasts [2–5]. We have previously
demonstrated that denosumab treatment of postmenopausal
women with low bone mass reduces bone remodeling and
increases bone mineral density (BMD) [10–13]. In women
with postmenopausal osteoporosis, denosumab therapy sig-
nificantly reduced the risk of new vertebral, hip, and non-
vertebral fractures at 3 years compared with placebo [14].
This agent has received regulatory approval in many countries
for treating women with postmenopausal osteoporosis at in-
creased risk or high risk for fracture.
Anti-resorptive agents, including denosumab, prevent
the progression of bone loss and improve bone strength
but do not restore trabecular architecture or cure osteo-
porosis. The salutary effects of denosumab on bone turn-
over and BMD resolve quickly upon discontinuation of
therapy [12], meaning that continued, long-term therapy
with denosumab is required to sustain the anti-fracture
benefit. The results of the 4-year phase 2 dose-ranging
study along with a 2-year interim analysis of the exten-
sion representing a total of 6 years of denosumab therapy
have previously been reported [10–13]. Here, we report
the final results of the 4-year extension of the phase 2
study, focusing on the skeletal effects, and safety and
tolerability of denosumab in subjects who received con-
tinued denosumab therapy for a total of 8 years.
Materials and methods
The details of both the original 4-year phase 2 study and the
extension study have already been published [10–13]. Those
methods are summarized below.
Study design
The open-label, 4-year study extension was performed in 23
centers in the USA. An institutional review board reviewed
and approved the study protocol at each center, and all
women provided written informed consent. The study was
performed in compliance with the FDA, International Con-
ference on Harmonisation (ICH) Good Clinical Practice
guidelines, and the World Medical Association Declaration
of Helsinki principles.
Subjects
The 412 women enrolled in the parent phase 2 study
were postmenopausal, ≤80 years old, and had a BMD
T-score between −1.8 and −4.0 for the lumbar spine, or
between −1.8 and −3.5 for either the total hip or fem-
oral neck. The subjects who agreed to participate in the
extension study had to have successfully completed the
parent study, including the end-of-study visit at month
48. Subjects were excluded if, during the parent study, they
had experienced severe and/or serious adverse events or ab-
normal laboratory results thought to be related to denosumab;
discontinued investigational product due to protocol-specified
BMD decrease during the study; missed two or more sched-
uled administrations of investigational product during year 3
or 4; used any bone active drugs; or developed a disease
known to affect bone metabolism.
Efficacy outcomes
Details of the assessment of BMD by dual-energy x-ray
absorptiometry (DXA) and the collection and measurements
of markers of bone turnover have been described previously
[11, 12]. During the extension study, DXA scans of the
lumbar spine, proximal femur, and one-third radius were
measured annually and were analyzed centrally. Serum bone
turnover markers, C-telopeptide of type 1 collagen (CTX)
and bone-specific alkaline phosphatase (BSAP), were col-
lected after an overnight fast and before the next dose of
denosumab at the extension study baseline (end of year 4 of
the parent study), and at 6-monthly intervals throughout the
study extension.
Reports of adverse events were collected at each visit
including information about new clinical fractures. Clin-
ical laboratory measurements for safety assessment in-
cluded standard hematology and serum chemistries that
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were performed at every visit in the study extension
through month 24 (chemistry performed also at month
25 or month 1 of year 3) and at the final visit at month
48. A central laboratory, Covance Laboratories (Indian-
apolis, IN) was used to analyze all hematology and
serum chemistry. Anti-denosumab binding antibody titers
were drawn at entry, month 1, 6, and 12, and then yearly
throughout the extension study. Antibody evaluation used
a validated electrochemiluminescent immunoassay, and a
cell-based assay was used to screen positive samples, as
previously described [10–12].
Treatments
Treatment groups in the parent study and the extension
study are presented in Fig. 1. The 200 subjects in the
extension study all received open-label denosumab
60 mg subcutaneously every 6 months (Q6M) with the
last dose administered at month 42 of the extension
study. Here, our efficacy findings focus on subjects
who received 8 years of continued denosumab in the
parent and extension studies, and those who received
placebo for 4 years in the parent study followed by
4 years of denosumab in the extension study. Although
subjects in the continued therapy group received differ-
ent regimens of denosumab during the parent study,
they were treated as a single group in the 4-year exten-
sion study. All subjects were included in the safety
analyses regardless of their previous treatment groups
(continued denosumab, intermittent denosumab [retreat-
ment and off-treatment], placebo, or alendronate). All
subjects were instructed to take daily oral supplements
of calcium (≥500 mg) and vitamin D (≥400 IU).
Statistical methods
All analyses were descriptive. No hypothesis testing was
performed since the primary objective of the study was
long-term safety of denosumab treatment. Sample size
was based on the number of subjects who completed
the parent study and were willing to participate in the
extension study. Summary statistics for continuous end-
points included mean, standard deviation, Q1, median,
and Q3 and the number of nonmissing observations.
For categorical endpoints, frequencies and percentages
were used.
Efficacy analysis included all subjects enrolled in the
extension study and had evaluable data for the time
point of interest. Percentage changes in BMD at the
lumbar spine, total hip, femoral neck, and one-third
radius over time were summarized using an analysis of
covariance (ANCOVA) model with the treatment groups
as the main effect, and geographical location and the
parent or extension study baseline BMD as covariates.
The least-squared means (LSM) and 95 % confidence
intervals (CI) of percent changes in BMD up to 8 years
are presented. Because the BTM values were skewed,
medians and interquartile ranges (1st quartile [Q1] to
3rd quartile [Q3]) were calculated.
Safety analysis included all subjects who had received
one or more doses of denosumab during the extension
study.
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Fig. 1 Study design of the 4-
year parent dose-ranging study
with the different treatment
regimens at months 24 and 48,
and the 4-year extension study
with all subjects receiving
open-label denosumab 60 mg
every 6 months. n0number of
subjects who enrolled in the
parent and extension study and
those that completed each study
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Results
Subjects
Baseline demographics for both the parent and extension studies
have been reported previously and are summarized in Table 1
[11, 12]. One hundred thirty-eight (69 %) of the 200 subjects
who enrolled in the extension study completed the 4-year study
(8 years since parent baseline; Fig. 1). The reasons for discon-
tinuation for the 62 subjects who did not complete the extension
study included withdrawal of consent (22), adverse event (8),
death (8), lost to follow-up (5), administrative decision (3), and
other (16). One hundred twenty-four (62 %) had received con-
tinued denosumab treatment during the parent study. Of these,
90 (73 %) completed the 8-year study assessment.
BMD and BTM assessments
Continued denosumab treatment cohort
For the subjects who received 8 years of continued denosu-
mab treatment and had evaluable data, BMD at the lumbar
spine and total hip significantly increased during the 4 years
of the extension study, while the BMD at the one-third
radius remained stable (Fig. 2). Compared with the parent
study baseline, eight continued years of denosumab treat-
ment was associated with mean BMD changes of 16.5, 6.8,
and 1.3 % at the lumbar spine, total hip, and one-third
radius, respectively (Fig. 2), and 6.8 % at the femoral neck
(data not shown). From the extension study baseline, BMD
increased at the lumbar spine by 5.7 % (Fig. 2a), total hip by
1.8 % (Fig. 2b), one-third radius by 0.8 % (Fig. 2c), and
femoral neck by 2.3 % on average (data not shown). At the
end of year 8, the serum CTX and BSAP remained below
parent study baseline with median reductions of 65 and
44 %, respectively (Fig. 3). The levels of reduction in both
CTX and BSAP at the end of the dose interval were similar
at all time points in the study extension.
Previous placebo cohort
In the subjects who received placebo during the 4-year
parent study, BMD increased at the lumbar spine, total hip,
and femoral neck with 4 years of denosumab treatment in
the extension study. From the extension study baseline,
BMD increased by 11.9 % at the lumbar spine (Fig. 2a),
5.6 % at the total hip (Fig. 2b), and 4.0 % at the femoral
neck on average (data not shown). BMD at the one-third
radius did not change during the extension study (Fig. 2c).
Subjects from the previous placebo group also responded to
denosumab treatment with reductions in CTX and BSAP.
Median values of both markers decreased to levels observed
in the subjects who had received continued denosumab
therapy (Fig. 3).
Other treatment cohorts
Independent of previous treatment in the parent study, BMD
and BTM responses in the other treatment groups (retreat-
ment, off-treatment, and alendronate) were similar to the
continued treatment group (data not shown). BTM reductions
in these smaller cohorts were similar to the continued deno-
sumab treatment group and remained within the premeno-
pausal reference ranges throughout the extension study.
Safety
All subjects in the study extension received one or more
doses of denosumab, and 142 subjects (71 %) received all
8 doses of denosumab. One hundred eighty-four subjects
(92 %) reported one or more adverse events. The 4 most
frequent adverse events were upper respiratory infection
(22.5 %), arthralgia (18.5 %), back pain (12.5 %), and
hypertension (12.5 %; Table 2), findings that were consis-
tent with what was reported during the 4 years of treatment
with denosumab or placebo in the parent study and the first
Table 1 Subject demographics and characteristics at baseline in parent and extension studies
Years 1–4 parent study Years 5–8 extension study
All subjects (N0412) Denosumab (N0319) Denosumab (N0200)
Age, years 62.5 (8.1) 62.3 (8.0) 66.1 (7.7)
Lumbar spine BMD T-score −2.14 (0.78) −2.14 (0.77) −1.55 (0.96)
Total hip BMD T-score −1.44 (0.71) −1.42 (0.69) −1.21 (0.73)
One-third BMD T-score −1.48 (1.21) −1.48 (1.18) −1.35 (1.19)
Albumin-adjusted calcium, mg/dL 9.77 (0.37) 9.77 (0.37) 9.86 (0.37)
Creatinine, mg/dL 0.76 (0.15) 0.76 (0.15) 0.83 (0.16)
Subjects who completed, n (%) 262 (64 %) 203 (64 %) 138 (69 %)
Values are mean (SD) unless indicated otherwise
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Fig. 2 Effect of 8 years of
continued denosumab treatment
on BMD at the a lumbar spine,
b total hip, and c one-third ra-
dius. BMD values are shown as
percent change from parent
study baseline (LSM+95 % CI
based on ANCOVA models
adjusting for geographical lo-
cation and parent study baseline
BMD values). Gray boxes in-
dicate the original 4-year parent
study. Numbers shown at each
time point reflect the number of
subjects enrolled in the exten-
sion study with observed data at
the selected time points of
interest
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2 years of the extension study. Three subjects (1.5 %) experi-
enced non-serious skin infections, and seven subjects (3.5 %)
reported other skin adverse events (eczema [3] and contact
dermatitis [4]); none of these events were related to the injection
site. Thirty-two subjects (16 %) experienced neoplasms, and of
these subjects, 24 subjects (12 %) experienced malignant or
unspecified neoplasms (Table 2). No difference was noted be-
tween the incidence of malignant or unspecified neoplasms
during the 4-year extension study period in the subjects who
received continued denosumab therapy for 8 years (15.3 %) and
those who received placebo for 4 years followed by denosumab
treatment for 4 years (13.0 %).
Serious adverse events occurred in 45 subjects (22.5 %;
Table 2). Seven subjects (3.5 %) experienced serious adverse
events of infection associated with hospitalization including
respiratory infection or pneumonia (5), endocarditis and staph-
ylococcal bacteremia (1), and diverticulitis (1). Eight subjects
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completion of the study from an adverse event that had occurred
during the study: one each from cardiac arrest, cardiac failure,
coronary heart disease, chronic obstructive pulmonary disease,
malignant hepatic neoplasm, metastatic ovarian cancer, pancre-
atic carcinoma, non-small cell lung cancer, and from an un-
known cause.
Nine subjects (4.5 %) sustained one or more osteoporotic
fracture during the 4-year extension study. There were no
reports of atypical femur fracture, delayed fracture healing,
or fracture non-union. No case of osteonecrosis of the jaw
(ONJ) was reported.
No unexpected trends in hematology or blood chemistries
were observed as previously reported [13]. No adverse events of
hypocalcemia were reported. No subject developed antibodies
to denosumab during the extension study.
Discussion
By inhibiting the effects of RANK ligand on osteoclast
proliferation and activity, denosumab is a potent inhibitor
of bone turnover. Because sustained therapy with denosu-
mab is thought to be necessary to achieve persistent anti-
fracture therapy, experience with long-term therapy is im-
portant. These data from the phase 2 study demonstrate that
the effects of denosumab on biochemical indices of bone
remodeling persisted over 8 years of therapy, and long-term
use of denosumab did not result in further inhibition of bone
metabolism. Denosumab induced continued increases in
BMD by DXA at the lumbar spine and total hip over the
8-year treatment period, with the final changes from base-
line being 16.5 % at the lumbar spine and 6.8 % at the total
hip. A similar pattern of progressive increase in spine BMD
with DXA has been observed over 10 years with alendro-
nate and 7 years with risedronate treatment, although the
magnitude of the response with denosumab appears to be
greater than with those anti-resorptive agents [15, 16]. How-
ever, the effect of denosumab on BMD at the proximal
femur appears to be different than the responses to other
anti-resorptive drugs. Total hip and femoral neck BMD
increased progressively over the entire 8-year treatment
interval whereas these values have been observed to plateau
after an initial increase with bisphosphonates. A continued
increase in hip BMD has also been observed over 5 years of
denosumab treatment in the much larger cohort of the piv-
otal phase 3 fracture study extension for the FREEDOM
study [17]. Several mechanisms could possibly explain the
progressive salutary effect of denosumab on hip BMD and
the possible difference in response compared with other
therapies. Denosumab is a more potent inhibitor of bone
resorption than oral bisphosphonates [11, 18]. Moreover,
unlike the response to oral bisphosphonate therapy, the
inhibition of bone resorption with denosumab is dynamic,
with maximal effect occurring shortly after dosing followed
by gradual release of the inhibition over the 6-month inter-
val before the next dose [10, 18]. Both of these effects could
result in a more positive balance in bone turnover than
occurs with other agents.
The progressive increases in proximal femur BMD
were not observed by DXA in the radius, another site
of predominately cortical bone, where BMD remained
stable but did not increase with long-term denosumab
treatment. However, using the more sophisticated imaging
techniques of quantitative computed tomography (QCT)
and high-performance peripheral QCT, denosumab thera-
py has been associated with increased cortical bone min-
eral content, increased cortical thickness, and improved
estimated strength in the radius and tibia [19, 20]. Deno-
sumab decreased porosity in the cortical bone (rib, tibia)
of non-human primates to a greater degree than with
Table 2 Adverse event summary
Adverse events overall
Years 5–8 extension study
Event, % (n) Denosumab (N0200)
Any adverse event 92.0 % (184)
Infections 60.5 % (121)
Malignant or unspecified neoplasmsa 12.0 % (24)
Osteoporotic fractures 4.5 % (9)
Serious adverse events 22.5 % (45)
Hospitalized infections 3.5 % (7)
Withdrawals due to adverse event 5.0 % (10)
Deaths 4.5 % (9)
Adverse events occurring in ≥10%
of subjects, % (n)
Upper respiratory infection 22.5 % (45)
Arthralgia 18.5 % (37)
Back pain 12.5 % (25)
Hypertension 12.5 % (25)
Pain in extremity 11.5 % (23)
Sinusitis 11.5 % (23)
Cataract 11.0 % (22)
Urinary tract infection 10.0 % (20)
N0all subjects who received one or more doses of study drug; n0
number of subjects reporting one or more events
a During years 5 to 8, 3 of the 23 subjects (13.0 %) who had previously
received placebo treatment developed a neoplasm (2 with basal cell
carcinoma and 1 with non-small cell lung cancer). Nineteen of the 124
subjects (15.3 %) who received continued denosumab therapy for 8 years
had a neoplasm (7 with basal cell carcinoma, 1 with basal cell carcinoma
and squamous cell cancer of the skin, 1 with bone neoplasm, hepatic
neoplasm, and lung neoplasm, 2 with lung neoplasm, 2 with breast
cancer, and 1 each with, Bowen’s disease, or cancer or neoplasm of the
colon, endometrium, ovary, pancreas, and thyroid). Two of the 17 sub-
jects (11.8 %) who received 210 mg denosumab during years 1 to 2 and
placebo treatment during years 3 to 4 developed a neoplasm (1 with basal
cell carcinoma and 1 with non-Hodgkin’s lymphoma)
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bisphosphonate therapy [21]. This effect is also very
different from the cortical response to teriparatide therapy
with which cortical porosity increased and cortical BMD
of the proximal femur decreased [22, 23].
This small phase 2 study and its extension were not
designed with adequate statistical power to determine
association between BMD changes with long-term deno-
sumab with improved effectiveness through reduction in
fracture risk. No study has adequately evaluated the pattern
of hip or nonvertebral fracture risk reduction over time. By
comparing the annual incidence of nonvertebral fractures
with long-term therapy (beyond 5 years) with that which
was observed during the first 3 years of treatment, the
FREEDOM extension study may provide the opportunity
to observe whether the continued effects on hip BMD and
cortical bone result in progressively better protection from
hip and nonvertebral fractures with long-term therapy.
Our report provides modest insight into the safety and
tolerability of denosumab therapy over 8 years. Although
safety of a treatment cannot be evaluated in such a small
cohort of subjects, no untoward effects with long-term
denosumab therapy were noted. The occurrences of ad-
verse events, serious adverse events, and deaths during
years 5 to 8 of therapy were similar to those observed
during the first 4 years of treatment with denosumab and
were consistent with the advancing age of the study
subjects. No evidence of unwanted skeletal effects of
sustained inhibition of bone metabolism (ONJ, atypical
femoral fractures, or impaired fracture healing) was ob-
served, and there was no signal of immune dysfunction.
Despite the length of our study, it has important
limitations. No placebo group exists after 4 years. This
and the small number of subjects completing the full 8-
year course of denosumab therapy markedly limit the
assessment of safety. While no clinical trial can identify
rare side effects of a therapy or adequately prove that a
drug is safe, the FREEDOM extension trial, by following
2 large cohorts for totals of 7 and 10 years, will help in
further characterizing the long-term safety of denosumab
over time.
In conclusion, these final results of a phase 2 study
and its extension demonstrate sustained effects of deno-
sumab therapy on bone remodeling and progressive,
substantial increases in BMD over 8 years in postmen-
opausal women with low bone mass. Treatment was
well tolerated, and the adverse event profile was con-
sistent with an aging population and was similar to
what has been reported previously. Long-term treatment
with denosumab is an effective treatment option for the
management of postmenopausal osteoporosis.
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